Bill's Feed
Nov 10, 2014

Merck 4-week hep C regimen with Gilead’s Sovaldi comes up short

Nov 9 (Reuters) – An attempt by Merck & Co to
shorten hepatitis C treatment to just four weeks by adding
Gilead Sciences Inc’s huge selling Sovaldi to its own oral
two-drug combination came nowhere near the desired efficacy due
to a high rate of relapses, according to interim data from a
midstage study.

Several companies have been working to find ways to further
reduce the number of weeks of treatment needed, while keeping
cure rates above 90 percent.

Nov 9, 2014

Insight: After hep C cure, companies target next big liver disease market

NEW YORK (Reuters) – Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.

Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said.

Nov 9, 2014

After hepatitis C cure, companies target next big liver disease market

NEW YORK (Reuters) – Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.

Several companies are working on treatments for hepatitis B, which can be controlled but not yet cured, and for fatty liver conditions caused by rising obesity, which without treatment could affect half of all Americans by 2030, according to the American Liver Foundation (ALF). Some of the drugs will address advanced fibrosis and cirrhosis, which are the scarring that virtually all liver diseases cause without effective treatments. Each of these drugs, once approved, could reach annual sales of as much as $10 billion, industry analysts said.

Nov 9, 2014

After hep C cure, companies target next big liver disease market

NEW YORK, Nov 9 (Reuters) – Now that new medicines promise
to cure millions of hepatitis C patients in coming years,
drugmakers including Gilead Sciences Inc are turning their
attention to other liver diseases, with a potential market that
could rival the success of statins, which generated more than
$30 billion a year in sales at their peak.

Several companies are working on treatments for hepatitis B,
which can be controlled but not yet cured, and for fatty liver
conditions caused by rising obesity, which without treatment
could affect half of all Americans by 2030, according to the
American Liver Foundation (ALF). Some of the drugs will address
advanced fibrosis and cirrhosis, which are the scarring that
virtually all liver diseases cause without effective treatments.
Each of these drugs, once approved, could reach annual sales of
as much as $10 billion, industry analysts said.

Nov 1, 2014

U.S. envoy Power defends Ebola guidelines, warns on Guinea

NEW YORK (Reuters) – The U.S. ambassador to the United Nations on Friday defended federal guidelines for monitoring health workers returning from three Ebola-stricken West African countries while urging greater coordination to contain the outbreak in Guinea.

There is a growing controversy in the United States over some states ordering 21-day quarantines for nurses and doctors returning after treating Ebola patients, an idea that medical experts have criticized.

Oct 31, 2014

U.S. envoy to U.N. defends Ebola guidelines; praises airlines

NEW YORK, Oct 31 (Reuters) – U.S. Ambassador to the United
Nations Samantha Power on Friday defended federal guidelines for
monitoring health workers returning from three Ebola-stricken
West African countries and praised the airlines still flying
there.

Amid controversy in the United States over some states
ordering 21-day quarantines for nurses and doctors returning
home after treating Ebola patients, Power said current federal
rules balanced “the need to respond to the fears that this has
generated” with the known science on the disease.

Oct 31, 2014

Samantha Power defends Ebola guidelines; praises airlines

NEW YORK (Reuters) – U.S. Ambassador to the United Nations Samantha Power on Friday defended federal guidelines for monitoring health workers returning from three Ebola-stricken West African countries and praised the airlines still flying there.

“Let me commend Air Brussels, Air France and Moroccan Airways for keeping their flights going. Those flights are a lifeline,” Powers said at a Reuters Newsmaker event in New York hours after returning from a four-day trip to Ebola-hit Liberia, Guinea and Sierra Leone, with a quick stop to drop her son off at school.

Oct 31, 2014

U.S. UN Ambassador defends Ebola guidelines; praises airlines

NEW YORK, Oct 31 (Reuters) – U.S. Ambassador to the United
Nations Samantha Power on Friday defended federal guidelines for
monitoring health workers returning from three Ebola-stricken
West African countries and praised the airlines still flying
there.

“Let me commend Air Brussels, Air France and
Moroccan Airways for keeping their flights going. Those flights
are a lifeline,” Powers said at a Reuters Newsmaker event in New
York hours after returning from a four-day trip to Ebola-hit
Liberia, Guinea and Sierra Leone, with a quick stop to drop her
son off at school.

Oct 30, 2014

PerkinElmer profit meets expectations; lowers forecast on forex

Oct 30 (Reuters) – PerkinElmer Inc on Thursday
reported lower-than-expected third-quarter sales and the
scientific instruments maker decreased its full-year earnings
forecast, citing the impact of the stronger dollar on foreign
exchange rates.

PerkinElmer gets more than half of its revenue from sales
outside the United States. Overseas sales in euros and other
major currencies were reduced when converted back into dollars.

Oct 30, 2014

Bristol immunotherapy shows promise in lung cancer trial

Oct 30 (Reuters) – Treatment of advanced squamous cell
non-small cell lung cancer (NSCLC) with Bristol-Myers Squibb
Co’s experimental immunotherapy nivolumab led to a
one-year survival rate of 41 percent in a midstage clinical
trial, according to data being presented at a medical meeting.

While the study called CheckMate-063 did not compare
nivolumab with another drug or placebo, the historical one-year
survival rate for patients like those in the trial, whose cancer
had progressed after treatment with two or more prior therapies,
is between 5.5 percent and 18 percent, the company said.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill